Ozempic and its Protective Factors in Relation to Acute Myocardial Infarction
Abstract
Abstract not found
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
Joshua Neumiller, Fredrick Lienhard, Radica Alicic, Katherine Tuttle (2017) Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors. 18(2), 106.
Brasil (2008) Vigitel Brasil 2007 -Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. 1-138.
(2006) Lee, Jong-Wook, (12 April 1945-22 May 2006), Director-General, World Health Organization, since 2003.
A Afshin, M Forouzanfar, M Reitsma (2017) Efeitos na saúde do sobrepeso e da obesidade em 195 países ao longo de 25 anos. 377(1), 13-27.
Donna Ryan, Ildiko Lingvay, Helen Colhoun, John Deanfield, Scott Emerson, Steven Kahn, Robert Kushner, Steve Marso, Jorge Plutzky, Kirstine Brown-Frandsen, Marianne Gronning, G Hovingh, Anders Holst, Henrik Ravn, A Lincoff (2020) Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. 229, 61-69.
Domenica Rubino, Niclas Abrahamsson, Melanie Davies, Dan Hesse, Frank Greenway, Camilla Jensen, Ildiko Lingvay, Ofri Mosenzon, Julio Rosenstock, Miguel Rubio, Gottfried Rudofsky, Sayeh Tadayon, Thomas Wadden, Dror Dicker, Mette Friberg, Anders Sjödin, Dror Dicker, Gabriella Segal, Ofri Mosenzon, Muhammad Sabbah, Yael Sofer, Victor Vishlitzky, Eelco Meesters, Mirelle Serlie, Arianne Van Bon, Helena Cardoso, Paula Freitas, Pedro Carneiro De Melo, Margarida Monteiro, Mariana Monteiro, Dírcea Rodrigues, Aysha Badat, Pankaj Joshi, Gulam Latiff, Essack Mitha, Hans Snyman, Elane Van Nieuwenhuizen, Olga González Albarrán, Assumpta Caixas, Carmen De Al Cuesta, Pedro Garcia Luna, Cristobal Morales Portillo, Pedro Mezquita Raya, Miguel Rubio, Niclas Abrahamsson, Johan Hoffstedt, Fredrik Von Wowern, Erik Uddman, Birgit Bach-Kliegel, Felix Beuschlein, Stefan Bilz, Alain Golay, Gottfried Rudofsky, Christopher Strey, Galyna Fadieienko, Nataliia Kosei, Tetiana Tatarchuk, Valentyna Velychko, Olesya Zinych, Stephen Aronoff, Harold Bays, Andrew Brockmyre, Robert Call, Charles Crump, Cyrus Desouza, Valerie Espinosa, Almena Free, Winston Gandy, Steven Geller, Gregory Gottschlich, Frank Greenway, Laurie Han-Conrad, Wayne Harper, Lee Herman, Mitzie Hewitt, Priscilla Hollander, Steven Kaster, Anastasios Manessis, Frederick Martin, Robert Mcneill, Alexander Murray, Paul Norwood, John Reed, Julio Rosenstock, Domenica Rubino, Martin Schear, Mark Warren (2021) Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. 325(14), 1414.
Anna Phillips, Jennifer Clements (2022) Clinical review of subcutaneous semaglutide for obesity. 47(2), 184-193.
Yixing Li, Paul Rosenblit (2018) Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?. 20(11), 113.
M Pedrosa, D Franco, H Gieremek, C Vidal, F Bronzeri, Cassia De, A Rocha, L De Carvalho Cara, S Fogo, F Eliaschewitz (2022) Agonista GLP-1 para Tratar a Obesidade e Prevenir Doenças Cardiovasculares: O Que Conseguimos até agora?. 24(11), 867-884.
(2022) Unknown Title.
Published
2023-12-27
Issue
Section
License
Copyright (c) 2023 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.